Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. In April 2014, Endo International PLC acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc.